The goal of this [type of study: randomized controlled clinical trial] is to [Determining the effect of prolotherapy use on the wound care process]. The main question it aims to answer is:
• [The use of proliferative substances in the care of 1st, 2nd and 3rd stage pressure injuries has a positive effect on the wound healing period].
Participants will [in patients with pressure injuries, wound irrigation with saline and wound irrigation with gelofusin were applied]. Researchers will compare [depth, length and width of the wound].

Start Date10 Jun 2023

Sponsor / Collaborator-

NCT03246659 / CompletedPhase 1IIT

Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma

The study is a phase I multicentre randomized, open, parallel-arm clinical trial conducted to investigate the IMP, namely 111In-CP04.
The study consists of preclinical (to establish a clinically useful formulation for the radiolabelled peptide CP04), and a clinical step. The main objective of the clinical part of the project is to establish the safety of i.v. administration of a high peptide amount and to assess the tracer biodistribution and dosimetry in MTC and normal tissues and to determine critical organs as well as the evaluation of the potential of CCK2 receptor scintigraphy to detect cancer lesions for both low (10ug) and high (50ug) peptide amount and the decrease of kidney dose after co-administration of gelofusine /gelaspan as a nephroprotective agent. To achieve this, the following study design has been accepted: the first 4 patients will receive 2 peptide amount of CP04: low peptide amount (for diagnostic purpose) and high peptide amount (for therapeutic purpose) of CP04. If no SAE is present, the remaining pts will be randomized for 2 arms: high peptide amount of 111In-CP04 with and without gelofusine/gelaspan infusion.
It is expected that CCK-2/gastrin receptor imaging will become a valid diagnostic method for a specific non-invasive staging and follow-up of patients with MTC, and treatment of recurrent and disseminated disease will be more efficient with minimized nephro- and myelotoxicity (if 111In labelled).

Start Date01 Aug 2016

Sponsor / Collaborator

Azienda Ospedaliero-Universitaria di Modena

[+4]

NCT02808325 / CompletedPhase 3

Prospective Controlled Randomized Double-blind Multicentre Study in Parallel Groups on the Efficacy and Safety of Gelaspan in Combination With Sterofundin ISO in Comparison With Gelofusine in Combination With Sodium Chloride Braun in Patients Scheduled for Abdominal or Pelvic Surgery

It is the objective of the study to investigate the efficacy and safety of two different volume replacement regimens with gelatine solutions.

Start Date01 Jun 2016

Sponsor / Collaborator

B. Braun Melsungen AG

100 Clinical Results associated with Succinylated Gelatin

100 Translational Medicine associated with Succinylated Gelatin

100 Patents (Medical) associated with Succinylated Gelatin

172

Literatures (Medical) associated with Succinylated Gelatin

01 Oct 2024·Perfusion

Changes in colloid oncotic pressure during cardiac surgery with different prime fluid strategies

Article

Author: Vonk, Alexander ; Loer, Stephan Alexander ; Beukers, Anne Maria ; Boltje, Jan Willem Taco ; Ie, Evy Loan Khiam ; Haumann, Renard Gerardus ; Bulte, Carolien Suzanna Enna ; Hugo, Juan de Villiers

Objective:

In cardiac surgery, colloid oncotic pressure (COP) is affected by haemodilution that results from composition and volume of prime fluid of cardiopulmonary bypass (CPB). However, the extent to which different priming strategies alter COP is largely unknown. Therefore, we investigated the effect of different priming strategies on COP in on-pump cardiac surgery.

Methods:

Patients ( n = 60) were divided into 3 groups ( n = 20 each), based on the center in which they were operated and the specific prime fluid strategy used in that center during the inclusion period. CPB prime fluids were either gelofusine-, albumin-, or crystalloid based, the latter two with or without retrograde autologous priming.

Results:

In all groups, COP was lowest after weaning from CPB and one hour after CPB. Between groups, COP was lowest with gelofusine prime fluid (16.4, 16.8 mmHg, respectively) compared with crystalloids (MD: -1.9; 95% CI:-3.6, -0.2; p = .02 and MD: -2.4, 95% CI: -4.2, -0.7; p = .002) and albumin (MD: -1.8, 95% CI: -3.5, -0.50; p = .041 and MD: -2.4, 95% CI: -4.1, -0.7; p = .002). In all groups, the decrease in COP one hour after bypass compared to baseline correlated positively with fluid balance at the end of surgery ( p < .001).

Conclusions:

COP significantly decrease during CPB surgery with the largest decrease in COP at the end of surgery, while at the same time fluid balance increases. We suggest that prime fluid strategy should be carefully selected when maintenance of COP during cardiac surgery is desirable.

01 Sep 2024·EUROPEAN JOURNAL OF PEDIATRICS

Efficiency of succinylated gelatin and amino acid infusions for kidney uptake reduction of radiolabeled αvβ6-integrin targeting peptides: considerations on clinical safety profiles

Article

Author: Weber, Wolfgang A ; Šimeček, Jakub ; Brosch-Lenz, Julia ; Nguyen, Nghia Trong ; Stangl, Stefan ; Notni, Johannes ; Kossatz, Susanne

Abstract:

Purpose:

68Ga-Trivehexin is an investigational PET radiopharmaceutical (NCT05799274) targeting αvβ6-integrin for PET imaging of carcinomas. 177Lu-D0301 is a structurally related therapeutic peptide tetramer. However, it showed considerable kidney uptake in rodents, impeding clinical applicability. We therefore evaluated the impact of different kidney protection strategies on the biodistribution of both agents in normal and tumor-bearing mice.

Methods:

Ex-vivo biodistribution of 68Ga-Trivehexin (90 min p.i.) and 177Lu-D0301 (90 min and 24 h p.i.) was determined in healthy C57BL/6N and H2009 (human lung adenocarcinoma) xenografted CB17-SCID mice without and with co-infusion of 100 µL of solutions containing 2.5% arginine + 2.5% lysine (Arg/Lys), 4% succinylated gelatin (gelofusine, gelo), or combinations thereof. Arg/Lys was injected either i.p. 30 min before and after the radiopharmaceutical, or i.v. 2 min before the radiopharmaceutical. Gelo was administered either i.v. 2 min prior activity, or pre-mixed and injected together with the radiopharmaceutical (n = 5 per group). C57BL/6N mice were furthermore imaged by PET (90 min p.i.) and SPECT (24 h p.i.).

Results:

Kidney uptake of 68Ga-Trivehexin in C57BL/6N mice was reduced by 15% (Arg/Lys i.p.), 25% (Arg/Lys i.v.), and 70% (gelo i.v.), 90 min p.i., relative to control. 177Lu-D0301 kidney uptake was reduced by 2% (Arg/Lys i.p.), 41% (Arg/Lys i.v.), 61% (gelo i.v.) and 66% (gelo + Arg/Lys i.v.) 24 h p.i., compared to control. Combination of Arg/Lys and gelo provided no substantial benefit. Gelo furthermore reduced kidney uptake of 177Lu-D0301 by 76% (90 min p.i.) and 85% (24 h p.i.) in H2009 bearing SCID mice. Since tumor uptake was not (90 min p.i.) or only slightly reduced (15%, 24 h p.i.), the tumor/kidney ratio was improved by factors of 3.3 (90 min p.i.) and 2.6 (24 h p.i.). Reduction of kidney uptake was demonstrated by SPECT, which also showed that the remaining activity was located in the cortex.

Conclusions:

The kidney uptake of both investigated radiopharmaceuticals was more efficiently reduced by gelofusine (61–85%) than Arg/Lys (25–41%). Gelofusine appears particularly suitable for reducing renal uptake of αvβ6-integrin targeted 177Lu-labeled peptide multimers because its application led to approximately three times higher tumor-to-kidney ratios. Since the incidence of severe adverse events (anaphylaxis) with succinylated gelatin products (reportedly 0.0062–0.038%) is comparable to that of gadolinium-based MRI or iodinated CT contrast agents (0.008% and 0.04%, respectively), clinical use of gelofusine during radioligand therapy appears feasible if similar risk management strategies as for contrast agents are applied.

01 Jul 2024·AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY

Mechanisms of gelofusine protection in an in vitro model of polymyxin B-associated renal injury

Article

Author: Kumar, Ashok ; Tam, Vincent H. ; Joshi, Aniket S. ; Roy, Anirban ; Hudson, Cole S. ; Li, Qingtian ; Sheikh-Hamad, David ; Yin, Taijun

Gelofusine is a gelatinous saline solution with the potential to attenuate polymyxin-associated nephrotoxicity. We demonstrated that the mechanisms of gelofusine renal protection involve reducing polymyxin B uptake by proximal tubule cells, limiting subsequent oxidative stress and apoptosis activation. In addition, gelofusine was more effective at reducing cellular injury than a known antioxidant control, methionine, and a megalin knockout cell line, indicating that gelofusine likely has additional pharmacological properties besides only megalin inhibition.

News (Medical) associated with Succinylated Gelatin

14 Sep 2022

·www.prnewswire.com

Global Enteral Collagen Peptide Protein Market to Reach $25.65 Billion

DUBLIN, Sept. 14, 2022 /PRNewswire/ -- The "Global Enteral Collagen Peptide Protein Market (2022-2027) by Form, Age Group, End User, Geography, Competitive Analysis, and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The Global Enteral Collagen Peptide Protein Market is estimated to be USD 17.14 Bn in 2022 and is projected to reach USD 25.65 Bn by 2027, growing at a CAGR of 8.4%. Market Segmentations The Global Enteral Collagen Peptide Protein Market is segmented based on Form, Age Group, End User, and Geography. By Form, the market is classified into Powder and Liquid. By Age Group, the market is classified into Pediatric (Below 18 years) and Adults (Above 18 year). By End User, the market is classified into Hospitals & Clinics, Homecare, and Nursing Home. By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific. Countries Studied America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas) Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe) Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA) Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific) Competitive Quadrant The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc. Ansoff Analysis The report presents a detailed Ansoff matrix analysis for the Global Enteral Collagen Peptide Protein Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach. The report analyses the Global Enteral Collagen Peptide Protein Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position. Based on the SWOT analysis conducted on the industry and industry players, the analyst has devised suitable strategies for market growth. Market Dynamics Drivers Increase in Prevalence of Chronic Disorders Growing Geriatric Population Increase in Number of Malnutrition Cases Restraints Poor Demand in Underdeveloped Countries Opportunities High Growth Potential in Emerging Countries Challenges Unavailability of Processing Technologies Key Topics Covered: 1 Report Description 2 Research Methodology 3 Executive Summary 4 Market Dynamics 5 Market Analysis 6 Global Enteral Collagen Peptide Protein Market, By Form 7 Global Enteral Collagen Peptide Protein Market, By Age Group 8 Global Enteral Collagen Peptide Protein Market, By End User 9 Americas' Enteral Collagen Peptide Protein Market 10 Europe's Enteral Collagen Peptide Protein Market 11 Middle East and Africa's Enteral Collagen Peptide Protein Market 12 APAC's Enteral Collagen Peptide Protein Market 13 Competitive Landscape 14 Company Profiles 15 Appendix Companies Mentioned Abbott Laboratories Cargill Danish Crown Darling Ingredients Dermarite Industries Fresenius Kabi Gelita Gelnex Global Health Products Italgelatine Junca Gelatines Medline Industries Medtrition Nitta Gelatin For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

20 Jul 2022

·www.biospace.com

Dura Substitute Market to Grow at a CAGR of 5.9% from 2022 to 2030

The global dura substitute market was valued at US$ 175.6 Mn in 2022 and is estimated to expand at a CAGR of 5.9% from 2022 to 2030 The global dura substitute market is expected to reach the value of US$ 328.6 Mn by the end of 2030 Analysts’ Viewpoint on Dura Substitute Market Scenario Healthcare providers in the dura substitute market are increasing efforts to improve the quality of life for patients with musculoskeletal disorders amid the ongoing coronavirus pandemic. It has been found that xenografts could cause complications such as graft disintegration, encapsulation, and scarring in patients. Hence, healthcare companies should increase R&D in regenerative medicine to overcome complications of xenografts. Download Sample @ Manufacturers are increasing the production of FDA-approved degradable materials such as biomimetic patch made of poly-L-lactic acid, which holds promising potentials to improve patient outcomes. Researchers have attempted to employ various synthetic polymers to make dural substitutes in order to minimize the spread of diseases caused by the use of allogeneic or xenogeneic materials for increasing clinical effectiveness and reduce costs. Rise in Number of Neurological Treatments Triggering Demand for Dura Substitutes The high prevalence of CNS (Central Nervous System) tumors caused by neurological disorders is emerging as a driver for companies in the dura substitute market. Chiari malformation and spinal cord related neurosurgery procedures are fuelling the demand for dura substitutes. The rise in the number of neurological treatments, such as duraplasty, is triggering the demand for dura substitutes. It has been found that in 2018, more than half of all dural substitutes were utilized in cranial and spine tumor surgeries. Healthcare Companies Increasing Availability of Grafts During Coronavirus Pandemic Healthcare services have been affected due to the ongoing coronavirus pandemic. Elective procedures have been postponed indefinitely in the dura substitute market. Neurosurgeons are being redeployed to treat COVID-19 patients. Recent cases of the Omicron variant are creating concerns for healthcare providers. Since coronavirus affects the brain of individuals, participants in the dura substitute market are improving their healthcare services to enable better patient outcomes. There is a requirement of compulsory training to the neurosurgeon community to understand the symptoms of the novel infection. As such, participants in the market are increasing the availability of biological grafts & synthetic grafts to ensure continuity in healthcare services. They are increasing efforts to revive R&D activities to gain proficiency in neurosurgical and spinal surgeries. R&D Investment and Regenerative Medicine Hold Potentials to Improve Surgical Outcomes Complications associated with dura substitute materials are affecting market growth. For instance, autologous tissue is generally preferred for commercialized dura replacements as it reduces the chances of infection and rejection. However, if there is insufficient local replacement tissue of sufficient quality to heal the dural defect, surgeons may avoid autografts. Hence, investments in R&D for materials and government initiatives to promote regenerative medicine hold promising potentials to improve surgical procedures. Since governments across the world are realizing the importance of regenerative medicine, such trends are translating into revenue opportunities for companies in the dura substitute market. Quick Buy This Premium Report From Here: Government Funding in Regenerative Medicine Contributing to Market Growth Government funding for the treatment of various diseases is increasing globally due to the formulation and adoption of supporting legislation & policies. Such trends are contributing to expansion of the regenerative medicine sector in the dura substitute market. Healthcare companies are drawing significant expenditure in regenerative medicines such as the establishment of centers of excellence, manufacturing infrastructure, and research networks, among others. The NIH (National Institutes of Health) Common Fund facilitated the establishment of the NIH Center for Regenerative Medicine in 2010 with the purpose of serving as a national resource for stem cell sciences. Such developments are helping to accelerate the development of novel medical applications and cell-based therapeutics. Transition from Animal Tissue-derived Materials to Synthetic Materials Aiding Market Growth Dural repair materials are transitioning from animal tissue-derived materials to synthetic materials as well as from inert to absorbable properties. Such findings are bringing a significant change in the global dura substitute market. Biomimetic patch is a new dural repair product that provides functional properties similar to alternate therapies. This patch has a 3 dimensional (3D) non-woven microfiber structure that is both mechanically strong and biocompatible. The animal investigation revealed that the biomimetic patch and commercially synthesized material groups demonstrated new subdural regeneration after 90 days, with low inflammatory response and minimal to no adhesion development at each stage. It has been found that the biomimetic structure and proper rate of degradation of the new absorbable dura replacement can lead significant regeneration of the dura mater. Dura Substitute Market: Overview Dural substitute is a type of medical device used in surgeries to repair dura mater, the outermost layer that covers and protects the brain. Animal collagen or nanofibers woven together with an elastic material to form a soft tamponade can also be used to create a dural substitute. Dural substitutes are required to prevent CSF leaks and to allow dural openings to heal after surgery. Dural substitutes can be biological or synthetic, harvested from animals or human cadavers, and used as an onlay or suturable grafts. The key advantage of using a dural substitute is that it is similar to the patient’s dura and can absorb and integrate into the host tissue. Rise in the number of road accidents and sports injuries, which increases the need of neurosurgery, is the major factor boosting market growth. However, product recalls is likely to hamper market growth. Dura Substitute Market: Key Drivers Prevalence of CNS tumors caused by neurological disorders is increasing. Chiari malformation and spinal cord tumor-related neurosurgery procedures that necessitate dural grafts have become more common. Rise in prevalence of neurological diseases requires neurosurgical treatments as well as duraplasty for effective and safe treatment outcomes. In 2018, more than half of all dural substitutes were utilized in cranial and spine tumor surgeries. This is expected to continue in the near future. Therefore, rise in prevalence of neurosurgical diseases leads to an increase in cranial and spinal duraplasty procedures, which in turn is anticipated to boost the demand for dura substitutes. Researchers have attempted to employ various synthetic polymers to make dural substitutes in order to minimize the spread of diseases caused by the use of allogeneic or xenogeneic materials, increase clinical effectiveness, and reduce costs Synthetic macromolecular materials, in comparison to collagen-based dura substitutes, lack the biological functions of stimulating cell migration and boosting the production of related cytokines. Scientists have attempted to create dura substitutes by incorporating gelatin or silk fibroin into the polymer. This approach not only assures the bionic structure of the dural replacement, but also enhances the material’s biological function and surface properties, improving its repair effects. Therefore, benefits such as enhanced clinical effectiveness, increased safety, and minimal adverse effects associated with synthetic dura substitutes are anticipated to fuel the growth of the dura substitute market Market Segmentation: Dura Substitute Market In terms of material, the global dura substitute market has been bifurcated into biological graft and synthetic graft. The biological graft segment has been split into autografts, allografts, and xenografts. The synthetic segment has been segregated into polytetrafluoroethylene and others. Based on application, the global dura substitute market has been classified into neurosurgery and spinal surgery In terms of end-user, the global dura substitute market has been divided into hospitals, ambulatory surgical centers, and others Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The dura substitute market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations. Regional Overview: Dura Substitute Market In terms of region, the global dura substitute market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa North America dominated the global dura substitute market in 2020, accounting for 41.8% share. Developed healthcare infrastructure and presence of patient-specific healthcare systems fuel the growth of the dura substitute market in North America. The U.S. dominated the market in North America due to rapid adoption of new technologies for soft tissue repair, presence of key players, and higher penetration of research activities across the country Moreover, growing burden of neurosurgical diseases is leading to increase in cranial and spinal duraplasty, which, in turn, is likely to boost the demand for dura substitute in the region Major Players The dura substitute market report concludes with the company profiles section, which includes key information about major players in the global dura substitute market Leading players analyzed in the report include Cook Medical LLC B. Braun Melsungen AG Integra LifeSciences Cousin Surgery W. L. Gore & Associates, Inc. Biosynth Lifesciences Acera Surgical, Inc. Medprin Medtronic Stryker DePuy Synthes Gunze Limited Baxter Bennett Health, Inc. RTI Surgical Natus Medical Incorporated Each of these players has been profiled in the dura substitute market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments Key Questions Answered in Global Dura Substitute Market Report What is the sales/revenue generated by dura substitute procedure across all regions during the forecast period? What are the opportunities in the global dura substitute market? What are the major drivers, restraints, opportunities, and threats in the market? Which regional market is set to expand at the fastest CAGR during the forecast period? Which segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period? What are the market positions of different companies operating in the global market? Segmentation Material Biological Grafts Synthetic Grafts Application Neurosurgery Spinal Surgery End-user Hospitals Ambulatory Surgical Centers Others Region North America Europe Asia Pacific Latin America Middle East & Africa Quick Buy This Premium Report From Here: You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333 About Us QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team). QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world. For Latest Update Follow Us: URL –

IPO

10 Jun 2022

·www.prnewswire.com

Insights on the Medical Collagen Global Market to 2028 - Rising Demand for Collagen-Rich Food & Beverages Presents Opportunities

DUBLIN, June 10, 2022 /PRNewswire/ -- The "Global Medical Collagen Market 2022-2028" report has been added to ResearchAndMarkets.com's offering. The global medical collagen market indicates that it would register growth at a CAGR of 6.57% in the projected years from 2022 to 2028. The growing public awareness about the benefits of collagen is a key factor fuelling the growth of the market. Besides, the rising demand for collagen from the medical devices industry is also aiding the market's growth. However, certain health-related issues that may occur as a result of collagen usage and a section of the population restricting the use of animal-derived products pose a challenge to this growth. On the other hand, there is still a large demand for collagen-rich food & beverages from people across the globe, which presents a growth opportunity for the market. Moreover, the growth of the cosmetics industry also indicates the vast potential for market growth as collagen is used substantially in many of these products. The global market for medical collagen covers North America, Europe, the Middle East and Africa, Latin America, and the Asia-Pacific. North America was the leading market globally in 2021, and is estimated to continue its reign until the end of the forecast period. It is known for being a developed region in all aspects. Further, the people here are also becoming significantly aware and conscious about their health. This has led to an increased demand for collagen-based products among people in the US and Canada. Consumers are including collagen in their diet in the form of food, drinks, and supplements. These factors are contributing to the growth of the regional market. The noteworthy players profiled in the medical collagen market are Lapi Gelatine, Symatese, Integra Life Sciences, Collagen Matrix Inc, DSM, Nippi Inc, Connoils LLC, Gelita, Jellagen, Stryker, Italgel, Darling Ingredients Inc, Tessenderlo Group, Weishardt, and Nitta Gelatin Inc. Integra Life Sciences is a renowned industry leader in the field of medical technology. Some of its famous brands include MatriStem UBMT, Integra, MediHoney, and ICP Express, among others. The US-based company was founded in 1989 and is headquartered in Princeton, New Jersey. In FY 2020, Integra's revenue and total assets increased in the fourth quarter. In Jan 2021, Integra Life Sciences acquired the regenerative medicine company Acell Inc. Post this acquisition, the company has been serving its customers more efficiently by offering them collagen-based wound management solutions. Key Topics Covered: 1. Global Medical Collagen Market - Summary 2. Industry Outlook 2.1. Impact of Covid-19 on the Medical Collagen Industry 2.2. Key Insights 2.2.1. Significant Investment in Research and Development Activities 2.2.2. Evolving Healthcare Industry 2.2.3. Launch of New Products Due to Increased Research 2.3. Porter's Five Forces Analysis 2.3.1. Threat of New Entrants 2.3.2. Threat of Substitutes 2.3.3. Bargaining Power of Buyers 2.3.4. Bargaining Power of Suppliers 2.3.5. Threat of Competitive Rivalry 2.4. Key Impact Analysis 2.4.1. Quality 2.4.2. Side-Effects 2.4.3. Product Effectiveness 2.4.4. Price 2.5. Market Attractiveness Index 2.6. Vendor Scorecard 2.7. Industry Components 2.8. Regulatory Framework 2.9. Key Market Strategies 2.9.1. Acquisitions 2.9.2. Product Launches 2.9.3. Partnerships 2.9.4. Business Expansions 2.10. Market Drivers 2.10.1. Increasing Demand from the Medical Devices Industry 2.10.2. Growing Public Awareness 2.11. Market Challenges 2.11.1. Health-Related Issues 2.11.2. Consumers Limiting the Use of Animal-Based Products 2.12. Market Opportunities 2.12.1. Growth of the Cosmetics Industry 2.12.2. Rising Demand for Collagen-Rich Food & Beverages 3. Global Medical Collagen Market Outlook - by Source 3.1. Bovine 3.2. Porcine 3.3. Other Sources 4. Global Medical Collagen Market Outlook - by Product 4.1. Gelatine 4.2. Hydrolyzed Collagen 4.3. Native Collagen 4.4. Other Products 5. Global Medical Collagen Market Outlook - by Application 5.1. Wound Care 5.2. Bone Grafts 5.3. Tissue Scaffolds 5.4. Cartilage Repair 5.5. Hemostats 5.6. Diagnostics 5.7. Vascular Grafts 5.8. Other Applications 6. Global Medical Collagen Market - Regional Outlook 7. Competitive Landscape 7.1. Gelita 7.2. Nitta Gelatin Inc 7.3. Nippi Inc 7.4. Italgel 7.5. Weishardt 7.6. Darling Ingredients Inc 7.7. Lapi Gelatine 7.8. Tessenderlo Group 7.9. Dsm 7.10. Collagen Matrix Inc 7.11. Connoils LLC 7.12. Integra Life Sciences 7.13. Symatese 7.14. Stryker 7.15. Jellagen 8. Research Methodology & Scope For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets

Acquisition

100 Deals associated with Succinylated Gelatin

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16568

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypovolemia	-	B. Braun Singapore Pte Ltd.	12 May 1995

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data